Opportunities
Search

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials. Distinctive Features: ·        The IIRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels. ·        Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. ·        Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel. ·        Programmatic review criteria include adherence to the intent of the IIRA, contribution to the VRP portfolio, relative impact, and relevance to military health. ·        The VRP may share FY26 IIRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Buyer: Pays de Chateaugiron communauté | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-11-13

Buyer: Stichting voor VO en MBO onderwijs op Reformatorische Grondslag | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-13

Buyer: Omnibusbetrieb Werner Vogel | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-13

Buyer: Miljødirektoratet | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13

Buyer: Cargotor Sp. z o.o. | Notice type: cn-standard | Procedure: comp-dial | Contract: works | Deadline: 2026-11-13

Buyer: SADEV 94 | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13

Buyer: СПЕЦИАЛИЗИРАНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ НА ХЕМАТОЛОГИЧНИ ЗАБОЛЯВАНИЯ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-13

Buyer: СПЕЦИАЛИЗИРАНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ НА ХЕМАТОЛОГИЧНИ ЗАБОЛЯВАНИЯ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-13

Buyer: Odense Kommune | Notice type: cn-standard | Procedure: oth-mult | Contract: services | Deadline: 2026-11-13

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through exami...

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hy...

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated mid-phase clinical trials of natural products(i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. All applications submitted under this NOFO must be supported by sufficient preliminary data demonstrating bioavailability (if applicable) and documentation that the natural product produces a reproducible and measurable impact on target engagement (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure target engagement in the patient population of interest or when there is a fundamental understanding of the products mechanism of action will this preliminary data requirement be waived. Applications submitted to this NOFO should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site efficacy trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy trial. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mi...

Buyer: SIEGVO | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-14

Buyer: SYNDICAT MIXTE FLANDRE MORINIE | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Gemeente Rotterdam | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Gemeente Rotterdam | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2026-11-16

Buyer: Etat de Vaud, DGNSI - Direction générale du numérique et des systèmes d'information | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Landratsamt Rosenheim | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Landratsamt Rosenheim | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Ministerie van Defensie | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-16

Buyer: Gestió de Serveis Sanitaris | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-16

Buyer: Gestió de Serveis Sanitaris | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-16

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ - Д-Р ГЕОРГИ СТРАНСКИ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-16